Decentralized and Hybrid Clinical Trials — Importance of Interoperability and Partnership
Technologies providing capabilities to conduct decentralized and hybrid clinical trials have existed for many years, but historically companies were slow to adopt them. The COVID-19 pandemic changed the landscape of clinical trials, accelerated the adoption of tools and highlighted the importance that interoperability and partnership play in achieving a successful end-to-end solution.
Decentralized aspects of clinical trials are becoming more widespread in the industry today and will continue to be commonly adopted through a hybrid approach. Technologies to support televisits, electronic consent and patient-reported outcomes are now a necessity.
The need for these and evolving technologies will continue to grow for many reasons. There is a rising movement in people, who work from home, moving out of cities, where most clinical research sites exist. People are living longer, and our aging population tends to have a more difficult time getting to a clinic regularly to be involved in a clinical trial. Most clinical trials are conducted on white males, and the industry has recognized the need to reach a more diverse population. This includes more research on women and people of different races and ethnic backgrounds. Many potential participants may not live close to clinical research sites or may not be able to frequently miss work to participate in a clinical trial. Recruiting a diverse population and decreasing patient drop-out rates requires making participation in clinical trials easier.
This webinar focuses on the various solutions needed for conducting decentralized clinical trials (DCTs)/hybrid clinical trials, including the interoperable technologies and partnerships required to provide the best patient experience.
Watch our webinar for ways to engage and retain patients and the factors to consider for implementing a successful end-to-end solution when evaluating or adopting technologies used in decentralized/hybrid clinical trials.